Hot Topics in Managing Syphilis

Khalil Ghanem, MD, PhD
Associate Professor of Medicine
Director, STD/HIV/TB Clinical Services
Baltimore City Health Department
Conflicts of Interest

• None
Objectives

• At the end of the presentation, attendees should be able to:
  – Describe the epidemiology of syphilis in Maryland and approaches to reducing reinfections
  – Interpret the reverse sequence testing algorithm for syphilis
  – Describe the situations where lumbar punctures are needed to diagnose neurosyphilis
Confusion

Dilemmas in the Management of Syphilis: A Survey of Infectious Diseases Experts

Syphilis in MD

- 2010: 285 early syphilis (ES) cases reported
- 2011: 424 ES cases reported

Data courtesy of Elisabeth Liebow and Cesar Pena
Who’s Getting Syphilis in MD?

Primary and secondary syphilis
- CASES: Maryland reported 452 cases in 2011.
- RATES: Maryland ranked 3 among 51 areas (48 states; Washington, DC; and 2 territories) reporting at least one case of P&S syphilis with 7.8 cases per 100,000 population compared to the U.S. rate of 4.5 cases per 100,000 population.

Rates of primary and secondary syphilis, by sex
- In Maryland, the rate among males was 14.4 per 100,000 population compared to the U.S. male rate of 8.2 per 100,000.
- The rate among females was 1.6 per 100,000 compared to the U.S. female rate of 1.0 per 100,000.

Rates of primary and secondary syphilis, by race/ethnicity
- In Maryland, the race/ethnicity adjusted rates per 100,000 population were 2.0 among whites, 20.9 among blacks, 2.8 among Hispanics, 1.2 among Asian/Pacific Islanders, and 0.0 among American Indians/Alaska Natives.
- The rate among blacks was 10.5 times that of whites.
- The rate among Hispanics was 1.4 times that of whites.

Congenital syphilis
- CASES: Maryland reported 24 cases in 2011.
- RATES: Maryland ranked 2 among 25 areas (23 states; Washington, DC; and 1 territory) reporting at least one case of congenital syphilis with a rate of 31.1 cases per 100,000 live births compared to the U.S. rate of 8.5 cases per 100,000.

### Diagnosis (YTD – 2013)

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary syphilis</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Secondary syphilis</td>
<td>33</td>
<td>8</td>
</tr>
<tr>
<td>Early latent syphilis</td>
<td>33</td>
<td>10</td>
</tr>
</tbody>
</table>
According to data from BESURE (National HIV Behavioral Surveillance System), HIV positivity among MSM in Baltimore was 38% in 2008 and 43% in 2011.

In Maryland last year, 92 of 158 (58%) P&S cases with known status were HIV infected [data courtesy of Cesar Pena, DHMH]
Syphilis Reinfection

• **23%** of MSM diagnosed with early syphilis from 2010-2011 had been diagnosed with syphilis in the preceding 4 years
  [Epi-Aid 2013-030: Laura Cooley, MD, MPHTM Alexa Oster, MD; Christine Ross, MD, MPHTM; Geoff Hart-Cooper]

• **30%** of HIV-infected persons with syphilis enrolled in the Johns Hopkins Clinical Cohort were retreated for syphilis within 5 years
  *CID* 2008; 47:258–65
What can we do?

• Every 3-month screenings among highly active MSM is very high-yield and cost efficient. Contact tracing is high-yield but costly. Screening in jails also appeared to be cost efficient.


• Mathematical models suggest that changes in behaviors and condom use, particularly short-term ones (and even long-term ones if they were only modest) would not impact syphilis rates and that frequent screening among very high risk individuals is probably what would have the most impact.

  Gray RT, et al. STD 2011;38: 1151-1158

• About 30% of high-risk MSM were not rescreened in the 6 months following therapy for syphilis.

  Marcus JL, et al. STD 2011; 38:24-29
Is More Penicillin Better in Early Syphilis?

- 579 HIV-infected participants with early syphilis from 7 hospitals in Taiwan between 2007 and 2012.
  - BPG 2.4 MU X1 (N=302) vs. BPG 2.4 MU X3 (N=277)
  - 70.9% serological responses in BPG X1 group vs. 76.7% in BPG X3 group

More is NOT better

Taiwan HIV and Syphilis Study Group. CROI 2013 Atlanta, GA Abstract S-119
Serological Testing for Syphilis

Traditional Algorithm

- RPR/VDRL
  - No further testing
  - Treponemal Test

Reverse Sequence Algorithm

- Treponemal Immunoassay (EIA/CIA)
  - No further testing
  - RPR/VDRL
    - No further testing
    - Confirmatory Treponemal Test
CIA

CIA (+)

RPR titer (Quantitative)

RPR (+)  Syphilis

RPR (-)  FTA

FTA (+)  Syphilis

FTA (-)  Syphilis Unlikely

CIA (-)

Report

No serological evidence of infection with *Treponema pallidum*. Incubating or early primary syphilis cannot be excluded.

Report

Evaluate clinically, determine if treated for syphilis in the past, assess risk of infection, and administer therapy according to CDC’s STD Treatment Guidelines if not previously treated.

Report

Syphilis positive:
- a) early syphilis
- b) past treated syphilis
- c) past untreated syphilis

Dr. Barbara Detrick

Immunology Laboratory
## The Antibodies

### Serological Tests For Syphilis

<table>
<thead>
<tr>
<th>Non-treponemal Tests</th>
<th>Treponemal Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complement fixation tests</td>
<td><em>Treponema pallidum</em> immobilization assay (TPI)</td>
</tr>
<tr>
<td>- Wasserman reaction</td>
<td>Fluorescent treponemal antibody absorption (FTA-ABS)</td>
</tr>
<tr>
<td>Flocculation Tests</td>
<td><em>Treponema pallidum</em> hemagglutination assay (TPHA)</td>
</tr>
<tr>
<td>- Rapid Plasma Reagin (RPR)</td>
<td><em>Treponema pallidum</em> passive particle agglutination assay (TPPA)</td>
</tr>
<tr>
<td>- VDRL</td>
<td>Enzyme Immunoassay (EIA)</td>
</tr>
<tr>
<td>- TRUST</td>
<td>Western Blot (WB) and Pseudoblots</td>
</tr>
<tr>
<td></td>
<td>Automated Chemiluminescence platforms</td>
</tr>
<tr>
<td></td>
<td>Chromatographic Point of Care (POC) tests</td>
</tr>
<tr>
<td></td>
<td>Microsphere Immunoassay</td>
</tr>
</tbody>
</table>
# Sensitivity and Specificity of Serologic Tests for Syphilis

<table>
<thead>
<tr>
<th>Test</th>
<th>Sensitivity during stage of infection, % (range)</th>
<th>Specificity, % (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Primary</td>
<td>Secondary</td>
</tr>
<tr>
<td>Nontreponemal tests</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VDRL [14]</td>
<td>78 (74–87)</td>
<td>100</td>
</tr>
<tr>
<td>TRUST [14]</td>
<td>85 (77–86)</td>
<td>100</td>
</tr>
<tr>
<td>RPR [14]</td>
<td>86 (77–99)</td>
<td>100</td>
</tr>
<tr>
<td>Early treponemal tests</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MHA-TP [15]</td>
<td>76 (69–90)</td>
<td>100</td>
</tr>
<tr>
<td>TPPA [16]</td>
<td>88 (86–100)</td>
<td>100</td>
</tr>
<tr>
<td>TPHA [17]</td>
<td>86</td>
<td>100</td>
</tr>
<tr>
<td>FTA-ABS [14]</td>
<td>84 (70–100)</td>
<td>100</td>
</tr>
<tr>
<td>Enzyme immunoassays</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG-ELISA [18]</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>IgM-EIA [19]</td>
<td>93</td>
<td>85</td>
</tr>
<tr>
<td>ICE [20]</td>
<td>77</td>
<td>100</td>
</tr>
<tr>
<td>Immunochemiluminescence assays</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLIA [21]</td>
<td>98</td>
<td>100</td>
</tr>
</tbody>
</table>

**NOTE.** CLIA, chemiluminescence assay; ELISA, enzyme-linked immunosorbent assay; EIA, enzyme immunoassay; FTA-ABS, fluorescent treponemal antibody absorption assay; ICE, immune-capture EIA; MHA-TP, microhemagglutination assay for *Treponema pallidum*; NA, not available; TPHA, *T. pallidum* hemagglutination assay; TPPA, *T. pallidum* particle agglutination; TRUST, toluidine red unheated serum test.
False Positive Serological Tests

• Lipoidal (RPR or VDRL)
  – Age
  – Pregnancy
  – Other infections (particularly viral)
  – Autoimmune diseases

• Treponemal
  – Other pathogenic treponematoses (yaws, pinta)
  – Non-pathogenic treponemes associated with necrotizing gingivitis and chronic periodontitis*
  – Lyme disease
  – Autoimmune diseases (rare)

* Riviere NEJM 1991: 325:539-43
Nontreponemal Serologic Tests

Advantages

• Rapid and inexpensive
• Can be done in clinic or office
• Quantitative
• Used to follow response to therapy
• Can be used to evaluate possible reinfection

Disadvantages

• May be insensitive in certain stages
• False-positive reactions may occur
• Prozone effect may cause a false-negative reaction
• Require laboratory technician to perform test and interpret results
Treponemal Serologic Tests

- **Principles**
  - Measure antibody directed against *T. pallidum* antigens
  - Qualitative (positive or negative)
  - Usually reactive for life (but may disappear over time)

- Treponemal tests include TP-PA, MHA-TP, FTA-ABS, ELISA, CIA
Advantages of RSA using CIA

• Efficiency
• Objectivity
• Cost-effectiveness in low prevalence settings
  – Increases specificity
  – Decreases laboratory tech time
• Comprehensive data
Positive Immunoassay & Negative RPR

Negative Confirmatory Treponemal Test

• False positive immunoassay
  – Be careful of pre-test probability

Positive Confirmatory Treponemal Test

• Old treated syphilis
• Old untreated syphilis
• Early syphilis
• Prozone reaction
The Hopkins Experience

• 4000 serological tests for syphilis/month
• 4-6 false positive CIAs/ month
• 10 indeterminate CIAs/ month that require further testing
Among the 1,000 samples tested, 15 were reactive by reverse screening compared to 4 by the traditional screening test. More false-positives detected with reverse algorithm. 6/15 tests were false +, 0/4 tests were false +. Reverse algorithm identified 2 patients with latent syphilis.
Risks: Negative RPR/VDRL with Positive Treponemal Tests

• Public Health Risks
  – Sexual transmission
    • Significant for early syphilis
    • None for latent syphilis
  – Vertical transmission
    • Significant for early syphilis
    • Unclear for late syphilis in the RPR/VDRL era
      – A new study suggests that vertical transmission with a persistently negative RPR is unlikely

• Risks to Individual
  – Risk of complications (i.e. disease progression)

50 year old asymptomatic newly divorced man with a past history of gonorrhea wants to be checked for sexually transmitted infections. Physical examination is normal. CIA+ RPR- TPPA+
He denies ever being treated for syphilis

32 year old woman at 24 weeks of gestation (no prenatal care) is seen in a local ED for abdominal pain. Examination is said to be unremarkable. Sent home. CIA+ RPR- TPPA+
Brought to STD Clinic where physical examination reveals a small painless vaginal ulcer that is darkfield positive. Patient treated for early syphilis.
Cost

• Costs to patients
• Cost Effectiveness
  – Cohort of 200,000: 1000 current infections and 10,000 previously treated infections
    • Reverse sequence algorithm treated 99% of the syphilis cases, but resulted in more overtreatment
    • Net cost per case treated was slightly higher for the reverse sequence algorithm ($1671 vs. $1621)
Outside the U.S.

GUIDELINE

IUSTI: 2008 European Guidelines on the Management of Syphilis

P French (Chair) FRCP, M Gomberg MD, M Janier MD PhD, B Schmidt MD, P van Voorst Vader MD and H Young MD

- A treponemal antigen test EIA or TPPA (preferred to TPHA) is recommended as a single screening test;
- The RPR/VDRL is not recommended as a primary screening test. It may be used for the rapid detection of symptomatic early syphilis in at-risk patients (supplemented with a standard recommended screening test). In these circumstances
Neurosyphilis

• There are no established criteria for the diagnosis of neurosyphilis

• Certain criteria that are used clinically:
  – Neurological symptoms
  – A positive CSF VDRL
  – Pleocytosis [$>5$ WBC/ml]
  – Elevated protein concentration [$>50$mg/dl]
Current CDC Recommendations for Lumbar Puncture

- All **neurologically symptomatic** patients
- **Asymptomatic** patients with tertiary syphilis
- All neurologically **asymptomatic** patients who don’t respond to therapy (i.e. lack of four-fold decline in RPR titers) and in whom reinfection is ruled out

- HIV+ patients with a CD4 count ≤350 cells/ml or RPR titer ≥1:32 are more likely to have CSF pleocytosis
A Failure of Prevention...

• Although some important unanswered questions persist and are the source of continued controversy, the lack of definitive answers to these questions is NOT the cause of increasing syphilis rates

• Aggressive primary and secondary prevention measures which are not controversial, which have been recommended since the dawn of the HIV epidemic, and which are critical to ensure successful responses are often not being implemented.
Acknowledgments

• DHMH
  – Barbara Conrad
  – Elisabeth Liebow

• BCHD
  – Patrick Chaulk
  – Glen Olthoff
  – Phyllis Burnett
  – Rafiq Miazid
  – Ravi Muvva

• CDC
  – Laura Cooley
  – Alexa Oster
  – Christine Ross
  – Geoff Hart-Cooper